RAS inhibitor daraxonrasib plus chemotherapy shrinks tumors in 61% of first-line pancreatic cancer patients
An early-stage trial of the oral RAS inhibitor daraxonrasib with chemotherapy showed a 61% response rate in metastatic pancreatic cancer. No control arm yet.
Summary
Pancreatic cancer is driven by mutated RAS proteins in the vast majority of cases, and a drug that blocks them is now being tested earlier in treatment. Daraxonrasib is an oral RAS(ON) inhibitor that targets active, GTP-bound RAS. In a phase I/II trial of 61 patients with metastatic pancreatic adenocarcinoma, adding it to gemcitabine and nab-paclitaxel as first-line therapy produced a confirmed response rate of 61%, including 8.2% complete responses. Median progression-free survival was 12.8 months, and 76.6% of patients were alive at 12 months. Those figures compare favorably with historical chemotherapy-only survival of 8.5 to 11.1 months. But this was a small, single-arm study with no randomized control group, so the comparison is indirect. A phase III trial, RASolute 303, must confirm the benefit. The drug is already FDA approved for previously treated disease.
Detailed Summary
Pancreatic ductal adenocarcinoma is among the hardest cancers to treat, and most cases are driven by mutations in RAS, a signaling protein long considered "undruggable." That makes any drug that shuts down RAS mechanistically important, and clinically significant for a disease where progress has been slow.
Daraxonrasib (Rasonque) is a first-in-class oral RAS(ON) multi-selective inhibitor. It targets GTP-bound, active forms of both mutant and wild-type RAS. In the phase III RASolute 302 trial in previously treated metastatic disease, it doubled overall survival and progression-free survival. On that basis the FDA approved it in August for patients who have had at least one prior systemic therapy or who cannot receive multi-agent therapy.
The new data move the drug to first-line use. In a phase I/II study of 61 patients, daraxonrasib plus gemcitabine and nab-paclitaxel produced a confirmed objective response rate of 61%, with 8.2% complete responses. Median duration of response was 11.1 months. Median progression-free survival was 12.8 months, with 51.7% progression-free at 12 months. Overall survival at 12 months was 76.6%. The presenting investigator, Wungki Park of Memorial Sloan Kettering, said this outpaces historical survival of 8.5 to 11.1 months with chemotherapy and could be transformative.
For patients and clinicians, this suggests that targeting RAS directly may eventually replace or reduce reliance on chemotherapy alone at the start of treatment. Those with metastatic pancreatic cancer may want to ask their oncologist about molecular testing, trial options and the approved second-line indication.
The caveats matter. This was a small, early-stage, single-arm study with no randomized control group, so comparisons with historical data are imperfect. The report excerpt does not detail safety or side effects, which need review. Results were presented at a conference and not yet peer reviewed. The phase III RASolute 303 trial will determine whether the benefit holds.
Key Findings
- Phase I/II, 61 patients with metastatic pancreatic cancer: daraxonrasib plus gemcitabine/nab-paclitaxel gave a 61% confirmed response rate, 8.2% complete.
- Median progression-free survival was 12.8 months; 12-month overall survival was 76.6%, versus historical chemotherapy medians of 8.5 to 11.1 months.
- Mechanism: oral RAS(ON) inhibitor blocking active GTP-bound mutant and wild-type RAS, the driver of most pancreatic cancers.
- Earlier phase III RASolute 302 doubled survival in previously treated disease, leading to FDA approval in August.
- Single-arm, no control group; phase III RASolute 303 must confirm first-line benefit. Safety data were not reported in this excerpt.
Methodology
This is a news report from MedPage Today on a phase I/II single-arm trial (n=61) presented at the EORTC-NCI-AACR symposium. It includes comments from the presenting investigator and an independent outside expert. Endpoints were response rate, duration of response, progression-free survival and overall survival, compared with historical controls.
Study Limitations
The study is small and non-randomized, and comparison with historical survival is indirect and prone to selection bias. The excerpt lacks safety and toxicity data and the article text is truncated. Verify details against the full presentation or peer-reviewed publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
